Advertisement
AXON vs CDXS
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Codexis (CDXS) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) is a large-cap public safety technology leader (market capitalization near $34.6 billion) with profitable, recurring revenue growth, while Codexis (CDXS) is a micro-cap biotechnology firm (market capitalization near $140 million) still investing ahead of scaled commercial revenue.
- Despite roughly 30%+ revenue growth, AXON has been under pressure recently — down about 43% over the past year — as a premium valuation reset amid the broader software sell-off.
- CDXS trades near $1.28, well below its 52-week high of roughly $2.98, but is up about 21% year-to-date on progress in its ECO Synthesis platform and an extended cash runway into 2028.
- The two business models differ sharply: AXON generates profits and recurring software revenue, while CDXS remains unprofitable and guides 2026 revenue to only $72–76 million.
- Risk profiles diverge: AXON faces valuation and government-budget risk, while CDXS carries execution, dilution, and adoption risk with a high beta (about 2.55, indicating amplified volatility versus the broader market).
- For further detail on each name, explore AXON Major News and AXON Today's Price Move, as well as CDXS Major News and CDXS Today's Price Move.
- To see how automated strategies are positioning across the market, explore the Trending AI Robots page.
Introduction
This comparison places two very different publicly traded companies side by side: Axon Enterprise, a dominant provider of TASER devices, body cameras, and public safety software, and Codexis, a developer of engineered enzymes and a manufacturing platform for RNA-based therapeutics. Investors weighing a large-cap, hardware-plus-software growth story against a speculative, pre-profit biotechnology platform may find the contrast instructive. The two names differ sharply in scale, profitability, momentum, and risk, making them useful reference points for understanding how market positioning and sector exposure shape relative performance in the current environment.
AXON Overview and Recent Performance
Axon Enterprise, based in Scottsdale, Arizona, sells connected public safety technology, including TASER energy devices, body-worn and in-car cameras, drones, and cloud software for digital evidence and records management. Its recurring software layer is a central growth engine: annual recurring revenue has reached about $1.6 billion, with net revenue retention around 126% and future contracted bookings near $15.1 billion.
Recent market activity has been volatile. After reaching record highs in mid-2025, AXON shares fell sharply through late 2025 and early 2026, caught up in a broad sell-off of software names even as fundamentals stayed strong. Revenue rose roughly 39% year over year in its latest quarter, and the company recently unveiled its Body 5 camera with enhanced AI processing. Analysts broadly retain a "Buy" consensus rating, though several have trimmed price targets. The shares now trade near $426, reflecting a reset of a valuation that previously carried a triple-digit forward price-to-earnings (P/E) ratio.
CDXS Overview and Recent Performance
Codexis, headquartered in Redwood City, California, uses its proprietary CodeEvolver platform to engineer enzymes for pharmaceutical manufacturing. The company operates a stable small-molecule biocatalysis business alongside its ECO Synthesis platform, an enzymatic route intended to scale the manufacture of RNA interference (RNAi) therapies — treatments that silence specific genes — such as siRNA (small interfering RNA) medicines.
In recent months, CDXS has made progress on its GMP (Good Manufacturing Practice) manufacturing facility and expanded engagement with contract development and manufacturing organizations (CDMOs) and the FDA's Emerging Technologies team. Still, revenue remains small: full-year 2026 guidance is $72–76 million, and the company reported a net loss of about $12 million in its latest quarter. Cash of roughly $54.9 million is expected to fund operations through 2028. The stock trades near $1.28, roughly 50% above its 52-week low but well below recent highs, reflecting both optimism about the platform and lingering dilution and execution concerns.
Trending AI Robots
Tickeron's Trending AI Robots page curates a focused selection of automated trading strategies from a much larger library of AI-powered bots. Tickeron hosts hundreds of AI trading bots that collectively monitor and trade thousands of different tickers, but only a subset earns a place in this featured section — those judged best suited to current market conditions. These bots span varied trading styles, strategies, timeframes, performance statistics, and sets of tickers, allowing users to compare approaches rather than settle for a single methodology. Traders and investors exploring systematic, data-driven signals can review the curated list to see which strategies are currently gaining traction. Visit Trending AI Robots to explore the available selection.
Head-to-Head Comparison
The core contrast is scale and maturity. AXON is a profitable, cash-generating operator with a hardware-to-software flywheel and entrenched relationships with public safety agencies; its principal challenge is valuation discipline and reliance on government budgets. CDXS, by contrast, is a pre-profit platform company whose value depends on future adoption of enzymatic nucleic-acid manufacturing — a larger potential market but one still years from validated scale.
Momentum also diverges. AXON has shown recent technical stabilization and a product catalyst, but its one-year total return remains deeply negative. CDXS has posted a positive year-to-date return, yet its daily swings are wide and its price remains below key moving averages, reflecting choppy sentiment. On risk, AXON's beta (about 1.44) is moderate for a growth stock, while CDXS's beta near 2.55 signals substantially higher volatility. Investors comparing the two are effectively choosing between a de-rated, high-quality compounder and a high-variance, early-stage biotech story.
Tickeron AI Verdict
Based on observable factors — trend consistency, earnings stability, recurring revenue durability, and the depth of the contract backlog — Tickeron's AI would likely favor AXON over CDXS in the current environment. AXON's established profitability, 126% net revenue retention, and a recent product catalyst offer a more consistent and measurable fundamental profile, even after a sharp valuation reset. CDXS presents a credible long-term option but currently carries higher uncertainty tied to clinical and manufacturing milestones, ongoing losses, and share dilution. The assessment is probabilistic rather than definitive and reflects relative positioning at a point in time, not a prediction of future prices.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and CDXS is a Hold.
AXON in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 55 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 30 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
CDXS's RSI Indicator recovers from oversold territory
The RSI Indicator for CDXS moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDXS advanced for three days, in 216 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CDXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDXS as a result. In 79 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for CDXS turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CDXS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.588) is normal, around the industry mean (3.498). P/E Ratio (-3.273) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.588) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CDXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON | CDXS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 54 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 83 | 100 | |
SMR RATING 1..100 | 81 | 98 | |
PRICE GROWTH RATING 1..100 | 66 | 82 | |
P/E GROWTH RATING 1..100 | 80 | 9 | |
SEASONALITY SCORE 1..100 | 30 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CDXS's Valuation (56) in the Chemicals Specialty industry is somewhat better than the same rating for AXON (90) in the Biotechnology industry. This means that CDXS’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that AXON’s stock grew similarly to CDXS’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as CDXS (98) in the Chemicals Specialty industry. This means that AXON’s stock grew similarly to CDXS’s over the last 12 months.
AXON's Price Growth Rating (66) in the Biotechnology industry is in the same range as CDXS (82) in the Chemicals Specialty industry. This means that AXON’s stock grew similarly to CDXS’s over the last 12 months.
CDXS's P/E Growth Rating (9) in the Chemicals Specialty industry is significantly better than the same rating for AXON (80) in the Biotechnology industry. This means that CDXS’s stock grew significantly faster than AXON’s over the last 12 months.
| AXON | CDXS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 71% | 2 days ago 87% |
| Advances ODDS (%) | 16 days ago 74% | 3 days ago 82% |
| Declines ODDS (%) | 2 days ago 70% | 10 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while CDXS’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- CDXS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while CDXS’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- CDXS’s TA Score: 4 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -27.37% price change this week, while CDXS (@Biotechnology) price change was -7.41% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.10%. For the same industry, the average monthly price growth was -0.96%, and the average quarterly price growth was -12.76%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
AXON is expected to report earnings on Mar 02, 2027.
CDXS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Aerospace & Defense (+5.10% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CDXS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To CDXS | 1D Price Change % | ||
|---|---|---|---|---|
| CDXS | 100% | -9.91% | ||
| AXON - CDXS | 43% Loosely correlated | -0.21% | ||
| VCYT - CDXS | 39% Loosely correlated | -7.18% | ||
| ARRY - CDXS | 36% Loosely correlated | -8.86% | ||
| TNYA - CDXS | 35% Loosely correlated | -5.94% | ||
| ZVRA - CDXS | 34% Loosely correlated | -1.81% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PCPP | 27.62 | N/A | N/A |
| Porter & Company Porter Portfolio Index ETF (PCPP) | |||
| RZG | 61.96 | -0.08 | -0.13% |
| Invesco S&P Smallcap 600 Pure Growth ETF (RZG) | |||
| DOCT | 47.84 | -0.14 | -0.29% |
| FT Vest US Equity Deep Buffer ETF - October | |||
| BSTZ | 25.34 | -0.18 | -0.71% |
| BlackRock Science and Technology Term Trust | |||
| SCA | 22.94 | -0.26 | -1.11% |
| GraniteShares Autocallable SMCI ETF (SCA) | |||